Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track INVA with free AI briefings, catalyst countdowns, and dilution alerts.

INVA · Innoviva, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand

CF+ Cash Runway

Follow INVA by email Get an email when INVA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INVA, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

May 2028 · Phase 1 · Recruiting · A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii
Registry primary completion date, not a results date
Jan 2029 · N/A · Recruiting · A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobact
Registry primary completion date, not a results date
Feb 2029 · Phase 2 · Recruiting · A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Trimethoprim-Sulfamethoxazole	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
Sulbactam	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
Moxifloxacin	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
IV Eravacycline 1.5mg/kg	Complicated Intra-abdominal Infections (cIAI)	Phase 2 · NCT06794541	Recruiting
Imipenem	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
Ethambutol	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
Ceftriaxone	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
Bedaquiline	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting
Azithromcyin	Mycobacterium Abscessus Pulmonary Disease	Phase 2 · NCT07485010	Not yet recruiting

Also used in these trials (approved or third-party drugs, not INVA's own candidates): Angiotensin Ii, Amikacin, Tigecycline, Rifabutin, Linezolid, Doxycycline, Clofazimine, Clarithromycin, Cefoxitin Sodium, Amoxicillin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INVA holds $1.1B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

No operating cash burn in latest filings
Share count +15% in a year +7

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INVA files for a raise →

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2025-11-05	—	NDA	+4.2%	+0.4%	+20.7%

Browse all historical PDUFA outcomes →

Get the full INVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z